GENERAL
Morepen Labs Files First ANDA, Eyes US Market With Sitagliptin Tablets
Morepen Laboratories Ltd has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitagliptin tablets USP in 25 mg, 50 mg and 100 mg strengths, marking the company’s entry into integrated finished dosage development and US regulatory filings. The submission expands Morepen’s established active pharmaceutical ingredient (API) […]
CW Bureau
·
Sep 28, 2026
GENERAL
Morepen Completes 1st Phase of API, CDMO Expansion Ahead Of Schedule
Morepen Laboratories has completed the first phase of its manufacturing capacity expansion programme ahead of schedule, increasing its installed reactor capacity for active pharmaceutical ingredients (API) and contract development and manufacturing organisation (CDMO) operations from 535 KL to 614 KL. The capacity addition is expected to strengthen Morepen Laboratories’ manufacturing readiness as the company scales […]
CW Bureau
·
Sep 7, 2026
GENERAL
Morepen Laboratories Sharpens API Focus, Enters CDMO Growth Lane
Morepen Laboratories is strengthening its position in the global Active Pharmaceutical Ingredients (API) market while expanding into the Contract Development and Manufacturing Organisation (CDMO) segment, according to Managing Director Sanjay Suri. In his message to shareholders in the company’s Annual Report 2026, Suri said Morepen continues to focus on manufacturing high-quality APIs for diverse geographies […]
CW Bureau
·
Sep 2, 2026
GENERAL
Morepen Lab Kicks Off Commercial Execution Of ₹825-Cr CDMO Order
Morepen Laboratories has completed its first commercial dispatch worth ₹50 crore under its ₹825- crore CDMO mandate and expects supplies of around ₹225 crore in Q2 FY2026-27 as it expands manufacturing capacity. Morepen Laboratories Ltd has commenced commercial execution of its recently announced ₹825 crore Contract Development and Manufacturing Organisation (CDMO) mandate by completing its […]
CW Bureau
·
Jul 1, 2026
GENERAL
Big-Ticket Global Win Shot In The Arm For Morepen’s Ambitions
Morepen Laboratories has secured one of the largest Contract Development and Manufacturing Organisation (CDMO) mandates in its history, winning a multi-year global order valued at around ₹825 crore ($91 million) from a leading international pharmaceutical major. The supplies under the agreement are expected to commence within the next four to five months, with execution scheduled […]
CW Bureau
·
Feb 23, 2026
